Downregulation of c-FLIPL could increase the PD-1 blockade efficacy in the B16 melanoma mouse model, indicating that PD-1 blockade may be more effective in patients with lower c-FLIPL expression, and that c-FLIPL may be the potential target to enhance the efficacy of immune checkpoint blockade. The gene discussed is CFLAR; the disease is melanoma.